Updates are available Correction dated 2023-03-03
Click to view Correction: https://doi.org/10.1186/s13023-023-02644-2
-
Authors
Manti, Filippo
Caviglia, Stefania
Cazzorla, Chiara
Dicintio, Annamaria
Pilotto, Andrea
Burlina, Alessandro P. https://orcid.org/0000-0002-2224-4706
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical
- License Information
-
More Information
Article History
Received: 28 April 2022
Accepted: 15 August 2022
First Online: 21 December 2022
Change Date: 3 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-023-02644-2
Declarations
:
: Not applicable.
: Not applicable.
: All authors received financial reimbursement from BioMarin at fair market value for their participation in virtual advisory boards. The manuscript was developed by the authors and reviewed by BioMarin. BioMarin provided project management; editorial and writing support was provided by an independent medical communication agency. F. Manti received advisory board honoraria from BioMarin; A. Pilotto is supported by IMI H2020 initiative (MI2-2018-15-06) paid to the university of Brescia Italian Ministry of Health paid to the university of Brescia; he received Lectures honoraria from Bial, BioMarin, Abbvie, Chiesi and Zambon pharmaceuticals-payment made to A. Pilotto as an individual; he received research support from Bial, BioMarin, Abbvie, Chiesi and Zambon pharmaceuticals-payment made to the Institution University of Brescia; S. Caviglia received advisory board honoraria from BioMarin; A. Dicintio received advisory board honorarium and speaker fee from BioMarin; C. Cazzorla received advisory board honorarium from BioMarin; A. Burlina received advisory board honorarium from BioMarin; A. Burlina received advisory board and lectures honoraria from Amicus Therapeutics, BioMarin, Chiesi, Freeline Therapeutics, PIAM, Sanofi, Takeda.
